The American Society of Nephrology (ASN) and 35 kidney care organizations wrote to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar, JD, to express their strong support and gratitude for the formation of KidneyX, a public-private partnership to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases.
In 2016, the Government Accountability Office (GAO) issued a report highlighting that Medicare spent $33.9 billion to manage kidney failure through Medicare’s End Stage Renal Disease (ESRD) program—more than 7 percent of all Medicare spending in 2015.[1]
The American Society of Nephrology (ASN) and 35 kidney care organizations wrote to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar, JD, to express their strong support and gratitude for the formation of KidneyX, a public-private partnership to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases.
In 2016, the Government Accountability Office (GAO) issued a report highlighting that Medicare spent $33.9 billion to manage kidney failure through Medicare’s End Stage Renal Disease (ESRD) program—more than 7 percent of all Medicare spending in 2015.[1]
“The GAO’s findings highlight the need for KidneyX, a public-private partnership to seed, incent, and accelerate breakthroughs to promising new therapies for people with kidney diseases. We believe that KidneyX is well-positioned to reduce the specific barriers that hinder innovation in the prevention, diagnosis, and treatment of kidney diseases, and propel private sector involvement,” wrote the organizations
KidneyX focuses on commercializing new therapies and providing a catalyst for investment by the private market in three specific ways not currently addressed by market forces or federal efforts by:
- De-risking the commercialization process
- Providing non-dilutive funding to seed, incent, and accelerate breakthroughs to promising innovators, selected through a competitive process.
- Offering participating innovators access to investors and business experts so that the kidney space is repositioned as an attractive and untapped market.
The organizations applauded “HHS’s efforts to launch KidneyX and for sending a clear message to investors and innovators that the kidney space is ready for and desires new therapies in the fight against kidney diseases.”
Please read the full letter on the ASN site .
[1] National Institutes of Health: Kidney Disease Research Funding and Priority Setting, GAO-17-121 (Dec. 2016)
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory